SCHEMBL3934473

SCHEMBL3934473

COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN(C)C)cc1)c1ccc2nccnc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.39
SMN1; SMN2 Q16637 5/20 0.39
RAB9A P51151 4/20 0.39
GAA P10253 3/20 0.39
NPC1 O15118 3/20 0.38
TP53 P04637 2/20 0.38
HTT P42858 2/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 6/20 0.35
MEN1 O00255 5/20 0.35
POLB P06746 4/20 0.35
LMNA P02545 1/20 0.35
AAK1 Q2M2I8 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
CASP1 P29466 1/20 0.34
TSHR P16473 1/20 0.33
SENP1 Q9P0U3 1/20 0.33
ALDH1A1 P00352 4/20 0.33
KDM4E B2RXH2 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5858317 1.00 MAPT (0.39) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL3943064 0.92 MAPT (0.38) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL5856770 0.92 MAPT (0.38) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL3935264 0.90 RAB9A (0.37) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL5859785 0.90 RAB9A (0.37) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL5856888 0.90 MAPT (0.37) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL3932867 0.90 MAPT (0.37) MAPTSMN1; SMN2RAB9AGAANPC1
SCHEMBL3942858 0.89 BACE1 (0.39) SMN1; SMN2KMT2AMEN1AAK1CTDSP1
SCHEMBL5858472 0.89 BACE1 (0.39) SMN1; SMN2KMT2AMEN1AAK1CTDSP1
SCHEMBL3944171 0.88 MAPT (0.35) MAPTSMN1; SMN2RAB9AGAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 EP disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 MAPT 1798/4885SMN1; SMN2 4299/4885RAB9A 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.